Alnylam Makes Board Changes
This article was originally published in Scrip
RNAi therapeutics company, Alnylam Pharmaceuticals, Inc. has appointed Michael Bonney, current board member and former CEO of Cubist Pharmaceuticals, chair of its board of directors – effective Jan. 1, 2016. John Clarke, founding investor and current chair, will remain on the board as a director. Former chair and CEO of Allergan, David Pyott, has also been appointed to Alnylam's board – effective immediately. In addition to serving as Cubist's CEO and a member of its board, Bonney was also previously its president and chief operating officer. He has also held various positions at Biogen, Inc. and prior to this he was at Zeneca Pharmaceuticals. Bonney has been a director of Alnylam since 2014 and is currently a director of the Celgene Corporation, the Whitehead Institute for Biomedical Research and the Gulf of Maine Research Institute. Pyott was CEO of Allergan from 1998 to 2015 and prior to this he was the head of Novartis nutrition division and a member of the executive committee of Switzerland-based Novartis AG. He is a lead director and member of the board of Avery Dennison Corporation and the supervisory board of Royal Philips in the Netherlands.